Objectives: Respiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is inexpensive. We investigated the efficacy of nebulized furosemide as an adjunctive therapy for COVID-19 respiratory failure.
Design: A double-blind, randomized, placebo-controlled trial.
Setting: Multicenter ICU study.
Patients: Adults requiring invasive mechanical ventilation secondary to COVID-19.
Intervention: Patients were randomized within 48 hours of intubation to receive inhaled furosemide or placebo until day 28, death, or liberation from mechanical ventilation.
Measurements And Main Results: The study was stopped early due to waning incidence of COVID-19; 39 patients were available for analysis with mean ± sd age of 70.5 (10.8) years, Acute Physiology and Chronic Health Evaluation II 26.1 (7.8) and Fio 60.0% (21.9). Baseline characteristics were similar between the groups. For the primary outcome of change in Pao/Fio ratio between day 1 and day 6, it was +31.4 (83.5) in the furosemide arm versus +20.1 (92.8) in the control ( = 0.58). For secondary outcomes, furosemide versus control: 60-day mortality was 48% versus 71% ( = 0.20), hospital stay was 25.6 (21.9) versus 27.4 (25.0) days, = 0.94 and VFD was 6.0 (9.1) versus 3.1 (7.1), value of equals to 0.28. A post hoc analysis of the hierarchical composite outcome, alive and ventilator-free favored furosemide. There were no adverse events.
Conclusions: In this trial of inhaled furosemide for COVID-19 respiratory failure, differences in Pao/Fio ratio to day 6 and other clinical outcomes were not significantly different, although the trial was underpowered due to early termination. Given the favorable profile of inhaled furosemide, further study is warranted in disease states where acute pulmonary inflammation contributes to the underlying pathophysiology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954058 | PMC |
| http://dx.doi.org/10.1097/CCE.0000000000001045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Asthma Exacerbations Using Machine Learning Models.
Adv Ther
November 2024
Global Development, Amgen Inc., One Amgen Center Dr, Thousand Oaks, CA, 91320, USA.
Introduction: Although clinical, functional, and biomarker data predict asthma exacerbations, newer approaches providing high accuracy of prognosis are needed for real-world decision-making in asthma. Machine learning (ML) leverages mathematical and statistical methods to detect patterns for future disease events across large datasets from electronic health records (EHR). This study conducted training and fine-tuning of ML algorithms for the real-world prediction of asthma exacerbations in patients with physician-diagnosed asthma.
View Article and Find Full Text PDFFabrication and evaluation of stable amorphous polymer-drug composite particles via a nozzle-free ultrasonic nebulizer.
Int J Pharm
May 2024
Department of Chemical Engineering (BK21 FOUR Integrated Engineering Program), Kyung Hee University, Yongin 17104, South Korea. Electronic address:
Article Synopsis
- * The technique effectively produces spherical composite particles that dissolve better in water compared to traditional crystalline drugs, offering potential improvements in how medications work in the body.
- * Despite some challenges like needing a continuous water supply and managing solvent solubility, this method stands out for its flexibility and ability to create uniform particles, marking a significant step forward in drug formulation and delivery.
Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study.
Crit Care Explor
February 2024
Kingston Health Sciences Centre, Kingston, ON, Canada.
Objectives: Respiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is inexpensive.
View Article and Find Full Text PDFAcute Hyperkalemia Management in the Emergency Department.
Adv Emerg Nurs J
January 2024
Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia (Dr Weant); and Department of Pharmacy, University of North Carolina Health, Chapel Hill (Dr Gregory).
Acute hyperkalemia is characterized by high concentrations of potassium in the blood that can potentially lead to life-threatening arrhythmias that require emergent treatment. Therapy involves the utilization of a constellation of different agents, all targeting different goals of care. The first, and most important step in the treatment of severe hyperkalemia with electrocardiographic (ECG) changes, is to stabilize the myocardium with calcium in order to resolve or mitigate the development of arrythmias.
View Article and Find Full Text PDFAdvances in Aerogels Formulations for Pulmonary Targeted Delivery of Therapeutic Agents: Safety, Efficacy and Regulatory Aspects.
Curr Pharm Biotechnol
September 2024
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Aerogels are the 3D network of organic, inorganic, composite, layered, or hybrid-type materials that are used to increase the solubility of Class 1 (low solubility and high permeability) and Class 4 (poor solubility and low permeability) molecules. This approach improves systemic drug absorption due to the alveoli's broad surface area, thin epithelial layer, and high vascularization. Local therapies are more effective and have fewer side effects than systemic distribution because inhalation treatment targets the specific location and raises drug concentration in the lungs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!